SIGi001-A-16

SIGi001-A-9 Bi-Allelic MAPT HA-tag

General#

Cell Line

hPSCreg Name
SIGi001-A-16
Alternative name(s)
SIGi001-A-9 Bi-Allelic MAPT HA-tag
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 20th April 2021
Notes SIGi001-A-9 (iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1) having a HA-tag at the C-terminal end of MAPT, Bi-Allelic
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Bioneer (BION)
Contact:
Bioneer (BION)
Owner Bioneer (BION)
Distributors

External Databases

BioSamples SAMEA6080815
CLO CLO_0103295
Cellosaurus CVCL_A7GT
Wikidata Q107116926

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research: allowed
Clinical: not allowed
Commercial: not allowed
Subclone of

Donor Information#

General Donor Information

Sex female
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Frontotemporal Dementia
In the original line SIGi001-A, no disease was diagnosed. In the line SIGi001-A-14, an HA-tag was added in homozygosity
Synonyms
  • Frontotemporal Dementia
Disease associated phenotypes
  • dementia
Family history no
Is the medical history available upon request? no
Is clinical information available? no

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA4447434

Ethics#

Also have a look at the ethics information for the parental line SIGi001-A .
Is there an MTA available for the cell line? Yes
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Bioneer
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation#

General

The source cell information can be found in the parental cell line SIGi001-A.
Passage number reprogrammed +15

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Genes
Is the used vector excisable?
No
Absence of reprogramming vector(s)?
Unknown
Reprogramming vectors silenced?
Unknown

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzymatically
Accutase
O2 Concentration 5 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SOX2
Yes
SSEA-4
Yes
TRA 1-81
Yes
SSEA-1
No
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Morphology

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: +15
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification#

Disease/phenotype related modifications
Frontotemporal Dementia
Synonyms
  • Frontotemporal Dementia
Genetic modifications
MAPT (target)
Isogenic modification
17
NM_001203252
Homozygous
An HA-tag has been added to the endogenous MAPT gene. The MAPT gene has a P301S and an Exon 10 + 16 mutation (both homozygous)
An HA-tag has been added to the endogenous MAPT gene. The MAPT gene has a P301S and an Exon 10 + 16 mutation (both homozygous)